NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
AstraZeneca
M.D. Anderson Cancer Center
Puma Biotechnology, Inc.
EMD Serono
National Cancer Institute (NCI)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)